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Summary
 
To mimic the sandfly pool feeding process and characterize the cellular and biochemical events
that occur during the early stages of promastigote–host interaction, we developed an ex vivo
model of human blood infection with 
 
Leishmania
 
 promastigotes. Within 30 s of blood contact,
 
Leishmania
 
 promastigotes bind natural anti–
 
Leishmania
 
 antibodies, which then activate the clas-
sical complement pathway and opsonization by the third component of complement. The op-
sonized promastigotes undergo an immune adherence reaction and bind quantitatively to
erythrocyte CR1 receptors; opsonized 
 
Leishmania
 
 amastigotes also bind to erythrocytes. Pro-
gression of infection implies promastigote transfer from erythrocytes to acceptor blood leuko-
cytes. After 10 min of ex vivo infection, 25% of all leukocytes contain intracellular parasites, in-
dicating that blood cells are the early targets for the invading promastigotes. We propose that
adaptation to the immune adherence mechanism aids 
 
Leishmania
 
 survival, promoting rapid pro-
mastigote phagocytosis by leukocytes. This facilitates host colonization and may represent the
parasite’s earliest survival strategy. In light of this mechanism, it is unlikely that infection-block-
ing vaccines can be developed.
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T
 
he Leishmanioses are a group of insect-transmitted
parasitic diseases caused by trypanosomatid protozoans
of the genus 
 
Leishmania.
 
 These protozoans have a hetero-
xenous life cycle, living first as sessile intracellular amasti-
gotes in the vertebrate host, then as motile flagellated
promastigotes in the gut lumen of the sandfly vector. Phle-
botomine sandflies are telmophage diptera that feed from
hematomas originated by laceration of superficial venules in
the host dermis, and transmit the disease by inoculating
promastigotes into the hematoma blood pool (1).
To understand the 
 
Leishmania
 
 infective process, it is crit-
ical to delineate the early sequence of events from promas-
tigote inoculation to its final entry into the macrophage (2).
After inoculation, the promastigote interacts with opsonic
serum factors and activates the complement system (3). The
third component of complement (C3)
 
1
 
–coated parasite ad-
heres to mononuclear phagocytes (MN) through CR1 and
CR3 complement receptors (CRs), and phagocytosis en-
sues without triggering the cells’ respiratory burst (4). The
promastigote then differentiates to the amastigote form
within the phagolysosome, where it replicates. The infec-
tion is thought to spread after extensive parasite prolifera-
tion, leading to macrophage death, amastigote release into
surrounding tissue, and entry into neighboring macro-
phages, all of which are aided by lymphatic and hemato-
genous dissemination of amastigotes and infected cells (5).
In vertebrate hosts, 
 
Leishmania
 
 parasites reside in MN;
therefore promastigote–host cell interaction has been ana-
lyzed extensively in vitro with MN (6–9), PMN (10), and
skin Langerhans cells (11). Promastigotes of several 
 
Leish-
mania
 
 species can also infect dendritic cells (12, 13), canine
sarcoma cells (14), and human fibroblasts (15), although the
route of entrance into sarcoma cells and fibroblasts does not
appear to reflect the natural course of infection. Promasti-
gote inoculation into the skin of laboratory animals has per-
 
mitted study of the inflammatory reaction to 
 
Leishmania
 
 and
has shown that the invading parasite interacts with my-
elomonocytic phagocytes before entering the macrophage
(16–19). Therefore, in vitro analysis of promastigote–MN
binding does not appear to reflect the first cellular interac-
tion that follows promastigote invasion of a susceptible host.
 
1
 
Abbreviations used in this paper:
 
 Ads-NHS, adsorbed NHS; AET, 2-ami-
noethyl isothiouronium; AO, acridine orange; C3, the third component
of complement; C3dg, degradation fragment of C3; CR, complement re-
ceptor; goat anti-
 
m
 
, goat anti–human immunoglobulin 
 
m
 
 chain; IA, im-
mune adherence; iC3b, inactivated C3b; MA, methylamine hydrochlo-
ride; MN, mononuclear phagocyte; NHS, normal human serum; NMS,
normal mouse serum; NRS, normal rabbit serum; PFS, PBS containing
2.5% FCS and 0.05% NaN
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In this study, we have analyzed the early stages of pro-
mastigote–host interaction in an ex vivo model of human
blood infection with 
 
Leishmania
 
 promastigotes. Within sec-
onds of blood contact, we observed that promastigotes are
opsonized by host natural antibodies that activate the classi-
cal complement pathway and deposit C3 on the parasite
surface. The C3-coated promastigotes undergo an immune
adherence (IA) reaction and bind to erythrocytes, thereby
enhancing parasite phagocytosis by blood leukocytes and
facilitates host colonization.
 
Materials and Methods
 
Parasites and Cultures. Leishmania  donovani
 
 Khartoum 1246
(MHOM/SD/43/124) and 
 
Leishmania amazonensis
 
 Maria
(MHOM/Br/79/Maria) isolates were provided by Dr. J.O. Hill
(Trudeau Institute, Saranac Lake, NY). Promastigotes were cul-
tured at 27
 
8
 
C in complete medium (RPMI 1640 supplemented
with 10% heat-inactivated FCS [Imperial Labs.], 2 mM
 
l
 
-glutamine, 100 IU/ml penicillin, and 100 
 
m
 
g/ml streptomycin)
until they reached the stationary phase. Parasites were harvested
by centrifugation (1,500 
 
g
 
, 15 min, 20
 
8
 
C), washed twice in PBS,
pH 7.2, and adjusted to the desired concentration.
 
Amastigote Isolation. L. amazonensis
 
 amastigotes were isolated
from the footpads of infected BALB/c mice. Lesions were re-
moved from the mice, the tissue disrupted, and amastigotes iso-
lated by Percoll gradient centrifugation (20).
 
Promastigote Labeling with [
 
111
 
In]-oxine.
 
In brief, promastigotes
(1–2 
 
3
 
 10
 
8
 
 cells/ml) were incubated for 10 min at 20
 
8
 
C in se-
rum-free RPMI 1640 medium with 0.1–0.2 mCi [
 
111
 
In]-oxine/
10
 
8
 
 cells (340 MBq/mg In, 1 mCi/ml; Amersham Int.). Promas-
tigotes were then sedimented (11,000 
 
g
 
, 1 min), the pellet washed
with PBS, adjusted to 10
 
7
 
 cells/ml in complete medium, and in-
cubated for 2 h at 27
 
8
 
C to allow release of poorly bound [
 
111
 
In]-
oxine. Promastigotes were then resedimented and the concentra-
tion adjusted. The specific activity of the labeled population
ranged from 0.7 to 0.9 cpm/cell.
 
Blood Collection and Cell Isolation.
 
Blood was drawn from
healthy donors into preservative-free heparin (10 IU/ml). A 50%
PBS-diluted blood sample was layered onto an equal volume of
72% Percoll (
 
d
 
 
 
5
 
 1.094; Pharmacia Biotech AB, Uppsala, Sweden)
and centrifuged (800 
 
g
 
, 30 min, 20
 
8
 
C), and the erythrocyte pellet
was washed twice by centrifugation (500 
 
g
 
, 5 min, 20
 
8
 
C) and re-
suspended in PBS. Leukocytes were fractionated into MN and
PMN populations (21), washed, and resuspended in PBS until use.
 
Antibodies and Sera.
 
Serum was prepared from healthy hu-
mans (NHS), rabbits (NRS), and mice (NMS) and stored in liq-
uid nitrogen. NHS was adsorbed (Ads-NHS) for 30 min on ice
with 
 
L. donovani
 
 promastigotes at a ratio of 1 ml of 50% diluted
NHS:10
 
9
 
 promastigotes. After incubation, the sample was centri-
fuged (11,000 
 
g
 
, 3 min) and the supernatant used for functional
assays. IgM, obtained as euglobulin after exhaustive dialysis
against distilled water, was freed of potentially contaminating IgG
by filtration through a HiTrap Protein G column (Pharmacia
Biotech AB). IgG was purified from the dialysate on a HiTrap
Protein G column. SDS-PAGE analysis confirmed that both
preparations were free of major contaminants. Mouse anti–
human erythrocyte antibody was obtained from mice hyperim-
munized with human erythrocytes. Rabbit anti–human CR1
receptor (R137) was donated by Prof. V. Nussenzweig and
co-workers (New York University Medical Center, New York)
and Dr. S. Rodríguez de Córdoba (Consejo Superior de Investi-
 
gaciones Científicas, Centro de Investigaciones Biólogicas, Madrid,
Spain). Goat anti–human immunoglobulin 
 
m
 
 chain (goat anti-
 
m
 
)
was from Southern Biotechnology Associates. The anti–human
CR1 mAb 543 (22) was from the American Type Culture Col-
lection (HB 8592) and mAbs 3D9 (23) and J3D3 (24) were pro-
vided by Prof. J. Schifferli (Kantonsspital, Basel, Switzerland).
The anti–human C3 
 
a
 
 chain mAb SIM 27-49 (IgG2b) was de-
veloped in our laboratory; both 3D9 and SIM 27-49 were puri-
fied from mouse ascites fluid by protein A chromatography. Puri-
fied human C3 was the gift of Dr. F. Vivanco (Fundación
Jiménez Díaz, Madrid, Spain).
 
Antibody Labeling with Sodium 
 
125
 
I.
 
Goat anti-
 
m
 
 (50 
 
m
 
g) or SIM
27-49 (25 
 
m
 
g) was labeled with 5 
 
m
 
l of sodium 
 
125
 
I (carrier-free,
105.36 mCi/ml; Du Pont/NEN) in Iodogen (Pierce Chemical
Co., Rockford, IL)-coated tubes for 5 min at 20
 
8
 
C. The
 
125
 
I-labeled antibody was isolated on a Sephadex G-25 column
(Pharmacia Biotech AB) equilibrated in PFS buffer (PBS contain-
ing 2.5% FCS and 0.05% NaN
 
3
 
). Labeled antibody–containing
fractions were pooled and specific activity was determined in a
gamma counter.
 
Immune Adherence Assay in Normal Human Blood.
 
Promastigote
binding to human cells was analyzed by adding 50 
 
m
 
l of 
 
111
 
In-
labeled promastigotes (10
 
7
 
 cells/ml) to 100 
 
m
 
l of heparinized
whole blood and incubating at 37
 
8
 
C for 1 min (all IA assay incu-
bations were carried out in a 37
 
8
 
C waterbath). The reaction was
terminated by transferring tube contents onto a 2-ml discontinu-
ous gradient of 1 ml 63% (
 
d
 
 
 
5
 
 1.077) and 1 ml 72% Percoll solu-
tions and centrifuging (500 
 
g
 
, 3 min, 20
 
8
 
C). Three gradient frac-
tions were collected, one each from the buffer-Percoll interface
(fraction 1), from the 63–72% Percoll interface (fraction 2), and
from the erythrocyte pellet (fraction 3); they were filtered
through glass fiber discs (GF/C; Whatman Int.) washed three
times in cold PBS, and the retained [
 
111
 
In] cpm were determined.
 
Measurement of the Immune Adherence Reaction Kinetics.
 
111
 
In-
labeled promastigotes (50 
 
m
 
l; 10
 
7
 
 cells/ml) were mixed with 100
 
m
 
l of heparinized blood and incubated at 37
 
8
 
C for varying time
periods (0–240 s). After incubation, the samples were layered
onto 1.5-ml 72% Percoll and centrifuged (500 
 
g
 
, 3 min, 20
 
8
 
C).
The Percoll solution (free parasites) and the erythrocyte pellet
(erythrocyte-bound parasites) were collected separately, and
processed as above. The promastigote viability is calculated for
each point by adding promastigote-retained [
 
111
 
In] cpm in the
upper and lower gradient fractions, and the 100% viability value,
as all promastigote [
 
111
 
In] cpm at time 0 of incubation. The
erythrocyte-bound promastigote profile is calculated as promas-
tigote-retained [
 
111
 
In] cpm bound to erythrocytes (lower fraction
only) relative to total viable parasites at each time point. The
analyses were performed in duplicate.
 
Immune Adherence On-Rate Constant (k
 
1
 
1
 
) Measurement in Hu-
man Blood.
 
Duplicate 50-
 
m
 
l samples of 
 
111
 
In-labeled promasti-
gotes (1–2 
 
3
 
 10
 
7
 
 cells/ml) and 100 
 
m
 
l of heparinized blood were
incubated at 37
 
8
 
C for varying time periods (0–240 s). Tube con-
tents were transferred onto 1.5 ml of 72% Percoll, centrifuged,
collected, filtered, and processed as before. A plot of log 
 
B
 
max
 
/
 
B
 
max 
 
2 
 
B
 
ti
 
 against incubation times (
 
t
 
i
 
) gives a straight line of slope
 
m
 
; 
 
B
 
max
 
 is the percentage of maximum promastigote binding, and
 
B
 
ti
 
 the percentage of promastigotes bound at times 
 
t
 
i
 
. Assuming
5 
 
3
 
 10
 
6
 
 erythrocytes/
 
m
 
l of blood, the erythrocyte concentration
[E] is 5.5 
 
3
 
 10
 
2
 
12
 
 M; 
 
k
 
1
 
1
 
 was calculated as 2.303 m/[E] mol
 
2
 
1
 
s
 
2
 
1
 
 (25) and is given as the mean 
 
6
 
 SEM of three experiments.
 
Binding Kinetics of NHS C3 and IgM Antibodies to Leishmania Pro-
mastigotes.
 
50 
 
m
 
l of a 2 
 
3
 
 10
 
8/ml promastigote suspension was
mixed with 50 ml of 50% untreated NHS or 50% NHS adjusted to27 Domínguez and Toraño
10 mM EGTA, 7 mM MgCl2 in PBS to block classical comple-
ment pathway activation (26), and incubated at 378C for varying
time periods. The reaction was terminated by addition of 1 ml of
cold (48C) PFS and promastigotes were washed twice by centrifu-
gation (11,000 g, 1 min, 208C). The cell pellet was resuspended in
0.2 ml of PFS containing 2 3 105 cpm of [125I]-SIM 27-49 (spe-
cific activity 107 cpm/mg) and incubated on ice for 1 h. Promasti-
gotes were then washed twice by centrifugation (11,000 g, 1 min)
in cold PFS and the [125I]-SIM 27-49 cpm bound was determined.
Promastigote C3b deposition dependence on both IgM and
IgG natural antibodies was analyzed by incubating 50 ml of a 2 3
108/ml promastigote suspension with 50 ml of 50% NHS, 50%
Ads-NHS, or 50% Ads-NHS supplemented with either 100 mg
of purified IgM or IgG at 378C for 3 min. Samples were then
processed as above and promastigote-bound [125I]-SIM 27-49
cpm was determined.
To analyze the kinetics of IgM binding to promastigotes, 50-ml
aliquots of 50% NHS were mixed with 50 ml of promastigotes (2 3
108 cells/ml) and incubated at 378C for varying time periods. The
reaction was terminated and promastigotes were washed three
times (11,000 g, 1 min) with cold PFS. The pellet was resus-
pended in 0.2 ml of PFS containing 2 3 105 cpm of 125I-goat anti-m
(specific activity 107 cpm/mg), incubated 1 h on ice, washed
twice as above, and promastigote-bound antibody was deter-
mined. For these analyses, duplicate samples were processed.
Equilibrium Constant (Kd) Measurement of the Immune Adherence
Reaction. 50 ml of 33% NHS and 50 ml of 111In-labeled promas-
tigotes (107 cells/ml) were mixed with 50 ml of each of nine
erythrocyte suspensions at concentrations from 1% (0.76 3 107
cells) to 30% (22.8 3 107 cells). Tubes were incubated at 378C
for 3 min. After incubation, tube contents were layered onto 1.5 ml
of 72% Percoll and centrifuged (500 g, 3 min, 208C). The Percoll
solution and the erythrocyte pellet were collected separately, fil-
tered, and erythrocyte-bound 111In-labeled promastigote cpm
were determined. Kd and Vmax values were obtained by direct lin-
ear plot (27), representing the number of erythrocyte-bound pro-
mastigotes at each erythrocyte concentration [Ei] tested (y-axis),
against erythrocyte concentration; in this case, each [Ei] point is
assigned its negative value on the x-axis.
Characterization of the Immune Adherence Reaction. To simplify
analysis of serum components and the nature of the erythrocyte
IA receptor, blood was replaced by NHS and washed erythro-
cytes. 50 ml each of 111In-labeled promastigotes (107 cells/ml),
50% or 33% NHS, and a 10% (vol/vol) washed erythrocyte sus-
pension were incubated at 378C for 3 min, gradient centrifuged,
collected, filtered, and processed as above. The analyses were per-
formed in duplicate.
To analyze IA dependence on divalent ions, 50-ml samples of
33% NHS were pretreated by incubating for 10 min at 208C with
varying concentrations (0–10 mM) of disodium EDTA. To test
the thermostability of serum factors involved in the reaction, se-
rum was incubated at 568C for 45 min. To investigate IA reac-
tion dependence on functional C3, NHS C3 and C4 thiolester
bonds were blocked with methylamine hydrochloride (MA) (28),
and then serum was dialyzed against PBS for 1 h at 48C. Control
or MA-treated samples were supplemented with purified C3 at a
final concentration of 0.25, 0.5, or 1.5 mg/ml, then assayed for
IA. IA reaction dependence on natural anti–Leishmania antibody
was analyzed by replacing 33% NHS with Ads-NHS or Ads-
NHS supplemented with IgM or IgG at a final concentration of
0.66 mg/ml.
To disrupt CR1 structure and function, erythrocytes were
treated with 2-aminoethyl isothiouronium (AET) (29). Erythro-
cytes were trypsin-digested as described (30); after incubation,
cells were washed twice in PBS, adjusted to 10%, and used in the
IA assay.
To block the erythrocyte IA receptor, aliquots of a 10% eryth-
rocyte suspension were incubated for 1 h on ice with pretitrated
dilutions of R137, mAbs 3D9, 543, J3D3, or mouse anti–human
erythrocyte antiserum. Heat-inactivated NRS, NHS, NMS, and
normal mouse IgG controls were used at the same dilutions as the
corresponding antibodies. After incubation, antibody-treated
erythrocytes were washed twice in PBS, adjusted to 10%, and
used in the IA assay.
Erythrocyte–promastigote IA rosettes were prepared by incu-
bating 50 ml of promastigotes (107 cells/ml) with 100 ml of hu-
man blood at 378C for 30 s (method A). A 5-ml aliquot was
gently dispersed into 1 ml of PBS and the IA rosettes examined
under a bright-field inverted microscope (320 phase-contrast
objective). Alternatively, 50 ml each of promastigotes, 33% NHS,
and a 10% washed erythrocyte suspension were incubated at
378C for 1 min (method B). After incubation, parasites were
stained with 1% acridine orange (AO) diluted 1:50,000 (31). A
10-ml aliquot was gently dispersed into 200 ml of PBS, and the IA
rosettes were examined in an UV-fluorescence microscope and
photographed.
Amastigote IA Assay. IA rosettes formed by human erythro-
cytes and opsonized amastigotes were prepared in duplicate with
50 ml each of a 10% washed erythrocyte suspension, amastigotes
(2 3 107 cells/ml), and 33% NHS, with or without 10 mM diso-
dium EDTA. In control samples, PBS replaced NHS. Samples
were incubated at 378C for 3 min; aliquots were then AO-stained
as before and amastigotes associated with three or more erythro-
cytes were counted as rosettes.
Leukocyte-dependent IA Rosette Dissociation. Blood samples were
divided into two aliquots; one was used as a control and the other
was centrifuged through 72% Percoll to isolate erythrocytes.
Erythrocytes were washed twice in PBS and resuspended in au-
tologous plasma to their initial concentration in blood. Duplicate
aliquots of 50 ml of the platelet- and leukocyte-depleted sample
or the untreated control were mixed with 50 ml of 111In-labeled
L. donovani promastigotes (107 cells/ml) and 50 ml of PBS, and
incubated at 378C for 0 to 30 min. At the end of each incubation
period, mixtures were centrifuged through 1.5 ml of 72% Percoll
(500 g, 3 min). Fractions containing the erythrocyte pellet and
the buffer-Percoll interface were collected separately, filtered, and
processed as before.
Promastigote Acceptor Capacity of Blood Leukocyte Populations.
Leukocyte acceptor capacity was analyzed in a two-step assay.
First, IA rosettes were preformed by method B; then 0.2 ml (5 3
107 cells/ml) of each of the leukocyte populations under study
(unfractionated leukocytes, PMN, and MN) and a PBS control
were added to four series of tubes containing preformed IA ro-
settes at a 20:1 leukocyte/promastigote ratio. Duplicate samples
were incubated at 378C for 0 to 30 min; after incubation, tube
contents were centrifuged through 1.5 ml of 72% Percoll (800 g,
3 min). Cells at the buffer-Percoll interface and the erythrocyte
pellet were collected separately, filtered, and processed as before.
Ex Vivo Infection Assay of Human Blood with Leishmania Promas-
tigotes. 1 vol of fresh heparinized blood was mixed with 1 vol of
a L. donovani promastigote suspension (107 cells/ml) and incu-
bated at 378C for varying time periods. Infection was terminated
by adding 1 vol of 0.4% paraformaldehyde in PBS, and tube con-
tents were then loaded onto 2 vol of 72% Percoll. After centrifu-
gation (850 g, 10 min), the leukocyte population at the plasma-
Percoll interface was collected, diluted with 20 vol of PBS, and28 Leishmania Infection by Immune Adherence
sedimented (500 g for 10 min). To reduce the number of contami-
nating free promastigotes, the leukocyte pellet was resuspended in
RPMI 1640 (5 ml medium/ml blood) and recentrifuged (80 g,
5 min). Cell monolayers were prepared in a Cytospin 2 centrifuge
(Shandon Southern Products) or as manually prepared cell smears.
The percentage of leukocytes with intracellular parasites was deter-
mined by microscopic examination of cell monolayers stained with
modified Giemsa reagent and photographed.
Results
Interaction of Leishmania spp Promastigotes with Normal Hu-
man Blood. To study promastigote fate during the period
immediately after their inoculation into humans and to de-
termine the host cell populations parasitized in hematoma,
we developed an ex vivo model of Leishmania spp infec-
tion. Data shown are for L. donovani and, when indicated,
for L. amazonensis promastigotes, although similar results
were obtained with Leishmania infantum and Leishmania ma-
jor (data not shown); they may thus be considered applica-
ble to Leishmania spp.
To mimic natural infection conditions, fresh human blood
from different donors was infected with 111In-labeled L.
donovani promastigotes and the blood–parasite mixture cen-
trifuged through a discontinuous Percoll density gradient to
separate cell populations and determine 111In-labeled pro-
mastigote distribution (Fig. 1). 1 min after promastigote
addition, nearly 100% of the parasites cosedimented with
the erythrocyte pellet. In contrast, promastigotes added to
EDTA-treated blood or mixed with PBS alone were located
at the Percoll-buffer interface after centrifugation. Promas-
tigote cosedimentation with erythrocytes was specific, unre-
lated to the erythrocyte blood group, and dependent on the
presence of serum factors and divalent ions in the reaction
mixture. These data show that the parasites bind by IA to
erythrocytes immediately after contact with host blood.
Kinetic and Promastigote Viability Profiles of the IA Reac-
tion. The kinetics are shown of erythrocyte–promastigote
(E-P) interaction and the promastigote viability profile over
a 4-min ex vivo infection period (Fig. 2). Within the first
30 s, the IA reaction has reached completion, and the pro-
mastigote inoculum binds completely to erythrocytes. To
calculate the on-rate constant (k11) of this reaction, it is as-
sumed that the E-P interaction occurs between cell parti-
cles (1,000:1 to 500:1 ratio) rather than between erythro-
cyte CR1 receptors and promastigote-bound C3b ligands.
In the incubation mixture [E] .. [P], and the interaction
is treated as a pseudo-first order process, giving a k11 value
of 3 3 1010 mol21 s21. Provided that promastigote-associ-
ated [111In] cpm parallels parasite viability, .90% of all via-
ble promastigotes remain erythrocyte-bound during the in-
cubation period. Promastigote viability was high during the
first 60 s of incubation; between 60 and 120 s, a sharp de-
crease in the initial erythrocyte-bound [111In] cpm was
observed due to complement lysis. A similar promastigote
lysis course is obtained by incubating 111In-labeled promas-
tigotes in the presence of 25% NHS; under these condi-
tions, the 111In-labeled promastigote half-life measured was
z90 s, by which time promastigote flagellar mobility was
already impaired (data not shown).
Promastigote Opsonization in the Presence of Nonimmune Se-
rum. Complement activation by Leishmania promastigotes
is believed to occur mainly through the alternative path-
way (3). The rapid kinetics observed for the IA reaction
suggested that this is not the case, for which the activation
pathway of the complement cascade by L. amazonensis
and L. donovani promastigotes was studied. Classical path-
way activation requires both Ca21 and Mg21, whereas the
Figure 1. Promastigote binding to human blood cell populations.
111In-labeled  L. donovani promastigotes (5 3 105 cells) were incubated at
378C for 1 min with 100 ml of (A) heparinized blood; (B) blood supple-
mented with 10 mM EDTA; and (C) PBS. After incubation, the samples
were centrifuged (500 g, 3 min, 208C) through a discontinuous Percoll
gradient. Three fractions (1–3), one each from the buffer-Percoll interface
(1); the 63–72% Percoll interface (2); and from the erythrocyte pellet (3)
were collected, processed as described in Materials and Methods, and the
percentage of [111In] cpm in each fraction determined. Data are the mean
values of duplicate samples from a representative experiment of seven
performed.
Figure 2. Kinetic and promas-
tigote viability course of the IA
reaction.  111In-labeled  L. dono-
vani promastigotes (5 3 105 cells)
were mixed with 100 ml of hep-
arinized blood and incubated at
378C for 0, 10, 20, 30, 60, 120,
and 240 s. After incubation, the
samples were centrifuged (500 g,
3 min, 208C) through 72% Per-
coll. The Percoll solution (free
parasites) and the erythrocyte pel-
let (erythrocyte-bound parasites)
were collected separately, filtered,
and the percentage of [111In] cpm
retained was determined. Pro-
mastigote viability (m) and eryth-
rocyte-bound promastigote (d)
profiles were calculated as de-
scribed in Materials and Methods.
Data are the mean value of dupli-
cate samples from a representative
experiment of three similar ex-
periments performed.29 Domínguez and Toraño
alternative pathway requires only Mg21; differential cation
chelation thus permits identification of the activation path-
way. In NHS adjusted to 10 mM EGTA and 7 mM
MgCl2, Ca21 is effectively chelated but free Mg21 is avail-
able for alternative pathway activation. The course of C3
deposition on the promastigote surface is shown in the
presence of 25% NHS or Mg-EGTA–treated 25% NHS
(Fig. 3 A). After 2–3 min of incubation, C3 binding
reaches a maximum and remains unchanged for the re-
mainder of the time course. In contrast, C3 deposition in
Mg-EGTA–treated serum follows a slower course that var-
ies depending on the Leishmania species studied.
The finding that Leishmania promastigotes activate com-
plement by the classical pathway prompted a search for
anti-Leishmania antibodies in NHS. In 25% NHS, promas-
tigotes are rapidly coated with IgG and IgM antibodies.
The kinetic profile of IgM binding to L. amazonensis and L.
donovani is shown (Fig. 3 B). IgM binding to both species
follows the same pattern, presenting a very rapid forward
reaction. After 30–60 s of incubation, IgM binding reaches
a maximum, followed by a rapid, marked release of the
bound antibody, amounting to z50% of that initially fixed.
IgG binding to the parasite follows a similar course (data
not shown). Promastigote C3 deposition dependence on
IgM or IgG binding was analyzed in the presence of NHS,
Ads-NHS with L. donovani promastigotes, and Ads-NHS
supplemented with IgM or IgG purified from the same se-
rum pool. After one adsorption cycle, Ads-NHS C3 deposi-
tion capacity was reduced to 15% of that of NHS. Ads-NHS
supplemented with purified IgM (100 mg) recovered 79% of
its initial activity. In contrast, IgG addition (100 mg) only
showed 24% activity recovery. Therefore, IgM binding to
promastigotes is required for promastigote opsonization.
Characterization of the IA Reaction. As the IA process is
strictly dependent on serum factor activity and the presence
of divalent ions in the incubation mixture, the role of these
Figure 3. Promastigote op-
sonization kinetics in NHS. (A)
Promastigote complement acti-
vation pathway in NHS (closed
symbols) and Mg-EGTA–treated
NHS (open symbols). Duplicate
aliquots (107 cells) of L. donovani
(d, s) and L. amazonensis (m,
n) promastigotes were incu-
bated at 378C in 25% NHS or 10
mM EGTA/7 mM Mg2Cl-
treated 25% NHS, for 0, 0.25,
0.5, 1, 2, 3, 4, 5, 7.5, 10, and 15
min. Promastigotes were then
washed twice by centrifugation
(11,000 g, 1 min) in cold PFS
and incubated 1 h on ice with
mAb [125I]SIM 27-49. After incubation, promastigotes were washed twice (11,000 g, 1 min) and [125I]SIM 27-49 cpm determined. C3 deposition is ex-
pressed as a percentage of the point of maximum [125I]SIM 27-49 binding. Data are the mean value of duplicate samples taken from one representative
experiment of three performed. (B) IgM binding kinetics to L. donovani and L. amazonensis promastigotes. Duplicate aliquots (107 cells) of L. donovani (d)
and L. amazonensis (m) promastigotes were incubated at 378C in 25% NHS for 0, 0.25, 0.5, 1, 2, 3, 4, 5, 7, and 10 min. After reaction, promastigotes
were washed three times (11,000 g, 1 min) with cold PFS and incubated for 1 h on ice with 125I-goat anti-m antibody. Results are expressed as the per-
centage of IgM binding relative to the point of maximum binding. Each point value represents the mean of duplicate samples taken from a representative
experiment of five performed.
Table I. Characterization of the IA Reaction
Concentration* IA reaction (%)‡
Serum treatment
Nil 93.2 6 3.0
Heat 56°C, 45 min 33% 6.4 6 0.3
EDTA 10 mM 9.7 6 1.6
MA 100 mM 9.0 6 1.1
PBS 1 C3 1.5 mg/ml 12.8 6 1.0
MA 1 C3 100 mM 1 1.5 mg/ml 41.9 6 1.0
Ads-NHS 16% 8.4 6 1.0
Ads-NHS 1 IgG 16% 1 0.66 mg/ml 16.2 6 1.3
Ads-NHS 1 IgM 16% 1 0.66 mg/ml 87.3 6 1.0
Erythrocyte treatment
Nil 88.0 6 2.0
Trypsin 153 IU/ml 6.0 6 0.4
AET 6.4% wt/vol 10.0 6 2.0
R137 1/10 8.4 6 1.0
NRS 1/10 89.0 6 3.0
Mouse anti-HRBC 1/2,000 89.0 6 7.0
NMS 1/2,000 89.0 6 1.8
mAb 3D9 10 mg/ml 6.4 6 0.8
mAb 543 10 mg/ml 92.0 6 0.6
mAb J3D3 1/20 90.0 6 0.3
NMIgG§ 10 mg/ml 92.0 6 0.7
*Final concentration in the assay.
‡IA reaction (%) was calculated as [111In] cpm in the erythrocyte pellet/
total [111In] cpm 3 100.
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factors and the nature of the erythrocyte IA receptor were
then studied. Serum and erythrocytes were subjected to
several treatments, and their capacity to sustain the IA reac-
tion tested (Table I). IA-promoting activity was lost from
serum after heat inactivation, in the presence of $1 mM
EDTA, or after blockage of C3/C4 thiolester bonds by
MA treatment. Purified C3 at physiological concentrations
cannot alone restore the serum activity; however, when
purified C3 was added to the mixture containing MA-
treated serum, the IA reaction was restored to 42% of posi-
tive control levels. Under these conditions, the partial IA
recovery must be due largely to alternative pathway C3b
deposition. In addition, Ads-NHS supplemented with
IgM, but not with IgG, recovers most of the IA capacity
lost through adsorption, indicating that IgM binding to
promastigotes is a prerequisite for the IA reaction.
The involvement of C3 suggested that erythrocyte CR1
participates in the IA reaction. To test this, erythrocytes were
treated with AET (29) or trypsin (30), which destroy or in-
activate CR1. In previous studies we confirmed (data not
shown), that erythrocyte CR1 recognition by rabbit anti-
CR1–specific antiserum (R137) decays in parallel to eryth-
rocyte incubation time with AET, and that AET-treated
erythrocytes no longer bind opsonized promastigotes; again,
Figure 4. Analysis of promastigote–erythrocyte interaction. (A) Dissociation (Kd) constant measurement. 50 ml each of 33% NHS and 111In-labeled
promastigotes (107 cells/ml) were mixed with 50 ml each of nine erythrocyte suspensions at concentrations ranging from 1 to 30% and incubated at 378C
for 3 min. After incubation, erythrocyte-bound promastigotes (d) were isolated by centrifugation (500 g, 3 min, 208C) through 72% Percoll, and [111In]
cpm determined. Kd and Vmax values were obtained by direct linear plot as described in Materials and Methods. The inset shows the first quadrant of the
plot, where the intersection points that allow Kd and Vmax calculation are clustered. Data are shown from one of two similar experiments. (B) Micro-
scopic analysis of the IA rosettes formed in normal human blood. Promastigote rosettes were formed by method A (Materials and Methods). A 5-ml aliquot
was dispersed into 1 ml of PBS and IA rosettes examined under a bright-field inverted microscope (3280). (C) Detail of an AO-stained promastigote ro-
sette. Rosettes were formed by method B (Materials and Methods), and stained with 1% AO diluted 1:50,000. A 10-ml aliquot was gently dispersed into
200 ml of PBS and the IA rosettes examined in an UV-fluorescence microscope (31,350).31 Domínguez and Toraño
after AET or trypsin treatment, no IA reaction was observed
(Table I). Anti-CR1–specific polyclonal antibody R137 and
mAb 3D9 blocked the E-P interaction in a dose-dependent
manner. In contrast, the reaction was not inhibited either by
the mAb 543 or the mAb J3D3, which recognize CR1
epitopes not directly related to the C3b binding site (22, 24,
32), or by mouse anti–human erythrocyte serum. As a con-
trol, preincubation of erythrocytes with NRS, NMS, or
normal mouse IgG had no effect on E-P interaction.
The dissociation constant (Kd) for the E-P interaction
was obtained from Langmuir saturation isoterm data (Fig.
4 A) plotted by the direct linear method (Fig. 4 A, inset);
the Kd value was either 2 3 107 (the erythrocyte number
binding 50% of the promastigote inoculum) or, in terms of
erythrocyte molarity, 2 3 10213 M.
Within 30 s of parasite addition to blood, promastigotes
and erythrocytes formed visible IA rosettes consisting of ag-
gregates of erythrocytes centered on a promastigote (Fig.
4 B). IA rosettes were also formed by method B, followed
by AO staining to permit visualization of the parasite sur-
rounded by erythrocytes in the complexes (Fig. 4 C).
Amastigote IA. To determine whether amastigotes also
undergo IA, they were isolated from L. amazonensis–infected
BALB/c mice and incubated with washed erythrocytes and
NHS as described in method B. NHS was replaced by either
PBS or EDTA-treated NHS in control samples. After incu-
bation, amastigotes were stained with AO and those with
three or more bound erythrocytes were counted as IA ro-
settes (Fig. 5 A). More than 90% of amastigotes were at-
tached to erythrocytes after 3 min of incubation (Fig. 5 B),
whereas no reaction was observed in controls.
Leukocyte-dependent IA Rosette Dissociation. Progress of in-
fection must imply transfer of promastigotes from IA
rosettes to leukocyte acceptor cells. Promastigote transfer
was studied with a cellular immune complex uptake assay
(33) used to test whether leukocytes affect IA rosette dissocia-
tion during an ex vivo infection. 111In-labeled promastigote
IA rosettes formed in normal and leukocyte-depleted blood
were incubated for varying periods of time and the parasite
fraction cosedimenting with erythrocytes was determined.
After 15 min of infection, z6% of the original IA rosettes
had dissociated in the leukocyte-depleted sample, com-
pared with 36% in the untreated sample (Fig. 6 A). Thus,
the promastigote dissociation rate in the presence of leu-
kocytes is sixfold more rapid than in their absence. The
promastigote acceptor capacity of unfractionated blood leu-
kocytes, PMN, and MN was then tested by incubating
111In-labeled promastigote IA rosettes with the isolated leu-
kocyte populations for varying periods of time. After each
incubation period, leukocytes and erythrocyte-bound pro-
mastigotes were separated by Percoll centrifugation, and
the [111In] cpm in each cell fraction determined. The kinetics
and percentages of promastigotes released from the IA
rosettes are shown (Fig. 6 B). In the presence of PMN,
which have the highest acceptor capacity, IA rosette disso-
ciation is very rapid, showing 79 and 93% promastigote re-
lease after 4 and 10 min of incubation, respectively, whereas
IA rosette promastigote dissociation in the absence of leu-
kocytes did not exceed 10%. After 4 min of incubation,
isolated PMN showed 1.5-fold higher acceptor capacity on
a per cell basis than did unfractionated leukocytes, and
approximately twice that of MN.
Figure 5. Amastigote IA. (A) AO-stained amastigote rosettes with human erythrocytes. Rosettes were formed as described in Materials and Methods.
After incubation, samples were stained and photographed (3790). (B) Amastigote IA reaction. 50-ml aliquots each of a 10% washed erythrocyte suspen-
sion, L. amazonensis amastigotes (2 3 107 cells/ml), and 33% NHS with or without 10 mM EDTA, or PBS as control, were incubated at 378C for 3 min.
After incubation, samples were AO-stained and amastigotes associated with two or more erythrocytes counted as IA rosettes. A, amastigotes; E, erythro-
cytes. Data are expressed as the mean values of duplicate samples. Similar results were obtained in two individual experiments.32 Leishmania Infection by Immune Adherence
After incubation and centrifugation, the parasites band to
the top of the Percoll solution, where they form large, low-
density IA complexes with leukocytes. If IA rosette dissocia-
tion is physiological, leukocytes should be engaged in active
parasite phagocytosis. To test this prediction, human blood
was infected ex vivo with promastigotes at a 1.5:1 parasite/
leukocyte ratio. The infection was terminated at different
time intervals, the leukocytes isolated, and cell smears were
Giemsa stained. After 5 min of incubation, numerous in-
fected leukocytes could be observed, and after 10 min,
z25% of the cells had intracellular parasites. At 60 min after
infection nearly all blood phagocytes were parasitized, and
their phagocytic efficiency was in the order PMN . MN .
eosinophils. Few apparently intact leishmanias were observed
in PMN and eosinophils, suggesting that these cells are en-
gaged in parasite lysis. In contrast, leishmanias within mono-
cytes showed a more clearly delimited morphology. Infected
lymphoid cells were not found.
Discussion
In natural leishmaniosis transmission, promastigotes un-
dergo a brief but critical encounter with host blood during
the sandfly blood meal. As macrophages are considered di-
rect targets of the invading parasites, it was of interest to as-
certain whether promastigotes interact with other host cell
lineages before taking final residence in the macrophage.
Therefore, we developed an ex vivo model of blood infec-
tion and found that upon contact with human blood, pro-
mastigotes are immediately coated by natural IgM and IgG
anti–Leishmania antibodies. Promastigote–IgM association
kinetics is very rapid, and parasite epitopes are saturated
within 1 min of incubation (Fig. 3 B). We have deter-
mined that anti–Leishmania antibodies comprise 15–30% of
total NHS IgM (z1.6 3 1027 M) (manuscript in prepara-
tion). As antibody activity depends on both its avidity and
its local concentration (34, 35), the velocity of the opsoniz-
ing reaction is not unexpected.
Fresh sera from most vertebrates contain natural antibod-
ies that react with Leishmania promastigotes (36, 37); in
nonimmune human sera, IgM and IgG antibodies have
been reported that bind and agglutinate Leishmania promas-
tigotes (38, 39), as well as IgG that recognize Leishmania
Gal a 1®3 Gal epitopes (40). In spite of data indicating
that IgM anti–Leishmania antibodies activate the classical
complement pathway and facilitate parasite phagocytosis
(41), there appears to be a consensus that, with the reported
exceptions of L. donovani (38, 39) and metacyclic peanut
lectin nonagglutinable L. major forms (42), promastigotes of
the genus Leishmania activate complement by the alterna-
tive pathway (43, 44). The results reported here show that
in humans natural IgM binding to Leishmania is the mecha-
nism that triggers activation of the classical complement
pathway. In 25% NHS, C3 binding to L. donovani and L.
amazonensis promastigotes reaches its maximum level after
2–3 min of incubation. Only when the classical pathway is
blocked with Mg-EGTA does C3 binding follow alterna-
tive pathway kinetics (Fig. 3 A). These results can safely be
extended to Leishmania spp, as similar complement activa-
tion patterns are also observed with L. major and L. infantum
promastigotes and with Crithidia choanomastigotes (data not
shown). Furthermore, the role of antibody in promastigote
opsonization contradicts the view that Leishmania invade
host cells by nonopsonic phagocytosis (45).
After incubation with human blood, the opsonized pro-
mastigotes bind to erythrocyte CR1, forming IA rosettes
(Fig. 4, B and C). The erythrocyte–promastigote–C3b in-
teraction is extremely rapid (k11 5 3 3 1010 mol21 s21) and
is complete within 30 s of initiation. The close parallel be-
tween Leishmania IA and the binding of opsonized immune
complexes to erythrocytes (46, 47) indicate that these reactions
share the same mechanism. For Leishmania, IgM binding
is a prerequisite for opsonization, and promastigote-bound
C3b is the only parasite ligand involved in erythrocyte
IA (Table I). Besides promastigotes, opsonized Leishmania
amastigotes also bind to human erythrocytes (Fig. 5, A
and B), suggesting that IA may contribute to amastigote
dissemination in the infected host. In addition to Leishma-
nia, erythrocyte CR1 participates in Plasmodium cytoadher-
ence to primate erythrocytes (48), and probably also plays a
part in red cell adhesion of serum-opsonized trypanosomes
Figure 6. Promastigote transfer from IA rosettes to leukocyte acceptor
cells. (A) Leukocyte-dependent IA rosette dissociation. For each time point,
duplicate aliquots (50 ml) of normal and platelet- and leukocyte-depleted
blood samples were incubated with 50 ml of 111In-labeled L. donovani promas-
tigotes (5 3 105 cells) and 50 ml of PBS, then incubated at 378C for 1, 2, 5,
7.5, 15, and 30 min. After reaction, tube contents were loaded onto 72% Per-
coll and centrifuged (500 g, 5 min). Fractions containing the buffer-Percoll
interface and the erythrocyte pellet were collected separately, filtered, and
[111In] cpm determined. Percentage of IA rosettes dissociated in normal blood
(d) and in the platelet- and leukocyte-depleted sample (m). Background IA
rosette dissociation after 1 min of incubation equals 4.5% of total [111In] cpm
released. Data are expressed as the mean 6 SEM of three experiments. (B)
Promastigote acceptor capacity of blood cell populations. 111In-labeled pro-
mastigote transfer was analyzed in a two-step assay. Duplicate samples of IA
rosettes, prepared by method B, were incubated at a 20:1 leukocyte/promas-
tigote ratio with unfractionated leukocytes, PMN, MN, and PBS at 378C for
0, 4, 10, and 30 min. After incubation, tube contents were loaded onto 72%
Percoll and centrifuged (800 g, 3 min). Cells at the buffer-Percoll interface
and the erythrocyte pellet were collected separately, filtered, and [111In] cpm
determined. Acceptor cell populations: PMN (j), unfractionated leukocytes
(d), MN (m), and PBS control (:). Data are the mean value of duplicate
samples from one representative experiment of four performed.33 Domínguez and Toraño
(49). We suggest that erythrocyte CR1 receptor–mediated
IA may thus have a paramount role in parasite invasion of
primates.
After the IA reaction, continuity of infection requires
that erythrocyte-bound promastigotes be shuttled to accep-
tor leukocytes through a cooperative mechanism involving
Leishmania-bound C3b and iC3b fragments and cell com-
plement CR1 and CR3 receptors (50, 51). Although it has
been proposed that promastigote Zn-proteinase (52) and
leukocyte CR1 receptors (53) participate in promastigote-
surface iC3b ligand generation, the erythrocyte CR1 re-
ceptor is the most logical physiological cofactor candidate
for the enzymatic degradation of promastigote-bound C3b
to iC3b by factor I. In addition to processing antigen-
bound C3b to iC3b and C3dg fragments, erythrocytes effi-
ciently enhance antigen-C3dg uptake by CR2 B lympho-
cyte receptors (54); this mechanism may well be exploited
by Leishmania parasites to divert the host protective im-
mune response.
In the ex vivo assay, at 10 min after infection, z25% of
blood phagocytes were parasitized in the same proportions
at which they are found in human blood (PMN . mono-
cytes . eosinophils), implying that there is no preferential
leukocyte target in early Leishmania infection. However, on
a per cell basis isolated PMN do engulf approximately
twice as many promastigotes as MN. Similar phagocytic ca-
pacity has been observed, although after much longer in-
fection periods, in isolated human blood leukocytes in-
fected in vitro with L. donovani amastigotes (55), and in
tissue samples analyzed shortly after promastigote inocula-
tion into hamsters (17) and mice (18, 19). These ex vivo
and in vivo experimental data, although seemingly identi-
cal, derive from different mechanisms. Based on the leuko-
cyte composition of murine blood (56), the expected
percentage of Leishmania-containing PMN after ex vivo in-
fection should be z16%, rather than the 90% observed in
the in vivo experiments. The ex vivo infection model
therefore provides information on the type and proportion
of leukocytes infected in situ, while in vivo data reflect the
cellular infiltrate in the parasite-triggered inflammatory re-
action. Nonprimate in vivo systems would thus appear to
be unsuitable for recreating the very different early Leish-
mania infection conditions in primates.
IA plays a central role in the clearance of opsonized mi-
croorganisms and foreign particles from the circulation via
their removal by phagocytes (57). Accordingly, we propose
that Leishmania adaptation to the host IA mechanism aids
parasite survival by promoting rapid promastigote phagocy-
tosis and leukocyte colonization. During Leishmania op-
sonization in human blood, promastigotes undergo three
continuous reactions: natural antibody binding, followed
by C3 deposition, followed by subsequent adherence to
erythrocytes. Each reaction proceeds at a different velocity
(Fig. 7). Promastigote–IgM binding and erythrocyte–pro-
mastigote IA are very rapid, whereas promastigote C3 dep-
osition by the classical pathway is a slower process. It is be-
lieved that IA proceeds faster than C3b deposition because
erythrocyte CR1 receptors cluster on the cell surface and
establish multipoint interactions with C3b ligands (58).
This cooperative effect increases in such extent the overall
CR1–C3b interaction avidity, that only very few C3b
molecules (between 60 and 3,000 molecules/cell) are re-
quired to produce a positive IA reaction (59). A similar
phenomenon appears to occur in Leishmania IA. Within 30 s
of ex vivo infection, .80% of Leishmania epitopes recog-
nized by IgM are occupied, the IA reaction is completed,
and promastigotes are being shuttled to blood phagocytes.
Complement lysis of parasites is still negligible at this time,
as only z5% (10,000 molecules) of the total C3 promasti-
gote acceptor capacity has been deposited. Since in the pres-
ence of 25% NHS, 50% [111In] cpm release from labeled
promastigotes is registered by 90 s, the IA mechanism
could substantially aid Leishmania survival through promo-
tion of promastigote phagocytosis by leukocytes, which
provide a safe haven for the parasite.
The results of this study modify the current view of human
Leishmania infection by emphasizing the fundamental role of
natural antibodies in triggering parasite opsonization and con-
firming that, under physiological conditions, promastigotes
activate complement only through the classical pathway. In
addition, these data show that, under physiological condi-
tions, Leishmania uses the IA mechanism to infect the host,
and suggest that this adaptation may be an extremely early
and very important parasite strategy for host invasion.
For some, immunoprophylaxis is the only hope for leish-
maniosis control (60). The participation of natural antibod-
ies in the mechanism used by Leishmania to infect the host
renders improbable the development of infection-blocking
vaccines. Emphasis should be placed on therapies aimed at
protecting the host against high parasite load, which should
limit disease transmission.
Figure 7. Kinetic profile of Leishmania IA reaction. The time course of
the opsonizing reactions involved in the Leishmania IA mechanism. IgM
binding (j), C3 deposition (m), and the promastigote–erythrocyte inter-
action (d) are taken from Fig. 3, B and A, and Fig. 2, respectively. Data
are expressed as a percentage of the point of maximum reaction.34 Leishmania Infection by Immune Adherence
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